Introduction: Prescribing practice in hospice/palliative care is largely extrapolated from other areas of clinical practice, with few studies of net medication effects (benefits and harms) in hospice/palliative care to guide prescribing decisions. Hospice/palliative care patients differ in multiple ways from better studied participant groups, hence the applicability of studies in other participant groups is uncertain. Haloperidol, a butyrophenone derivative and dopamine antagonist, is commonly prescribed for nausea, vomiting, and delirium in hospice/ palliative care. Its frequent use in delirium occurs despite little evidence of the effect of antipsychotics on the untreated course of delirium. The aim of this study was to examine the immediate and short-term clinical benefits and harms of haloperidol for delirium in hospice/palliative care patients. Method: A consecutive cohort of participants from 14 centers across four countries who had haloperidol commenced for delirium were recruited. Data were collected at three time points: baseline, 48 hours (clinical benefits), and day 10 (clinical harms). Investigators were also able to report clinical harms at any time up to 14 days after it was commenced. Results: Of the 119 participants included, the average dose was 2.1 mg per 24 hours; 42 of 106 (35.2%) reported benefit at 48 hours. Harm was reported in 14 of 119 (12%) at 10 days, the most frequent being somnolence (n = 11) and urinary retention (n = 6). Seven participants had their medication ceased due to harms (2 for somnolence and 2 for rigidity). Approximately half (55/119) were still being treated with haloperidol after 10 days. Conclusion: Overall, 1 in 3 participants gained net clinical benefit at 10 days.
Introduction
Delirium is a common and distressing symptom for many patients and families as the end of life approaches 1,2 and if no reversible factors are present, is an indicator of poor prognosis.
Haloperidol is a butyrophenone derivative and dopamine antagonist. It is commonly prescribed for nausea, vomiting, and delirium in hospice/palliative care. [3] [4] [5] Its use in delirium occurs despite little placebo controlled evidence that antipsychotic medication changes the natural history of delirium. Although open label studies or randomized trials comparing two antipsychotics have shown improvement of delirium scores over time, 2 this may relate to the natural history of delirium, which is to resolve over time as precipitants are treated and reversed. The three studies [6] [7] [8] with placebo arms have methodological problems (inadequately powered, inadequate allocation concealment).
Current international guidelines suggest targeted use of antipsychotics for severe behavioral disturbance in delirium 1 with cautious dosing and close monitoring. 9 The potential harms of haloperidol include: central effects (sedation, insomnia, restlessness, anxiety, euphoria, confusion, urinary incontinence, grand mal seizures); cardiovascular effects (tachycardia, hypotension, conduction irregularities); and extrapyramidal effects (akathisia, dystonia, and persistent tardive dyskinesia). 5 More rarely, haloperidol has been reported to cause neuroleptic malignant syndrome and hematological abnormalities including leucopenia, leucocytosis, and anemia. Although widely prescribed, the benefits and harms of haloperidol for delirium have not been well quantified in hospice/palliative care patients.
Much of the prescribing practice in hospice/palliative care has been extrapolated from related areas of clinical practice with populations that are more readily studied. Due to limited available evidence, an international initiative was commenced in 2011 to improve clinicians' understanding of the net clinical effects of key medicines used in hospice/palliative care and to further inform prescribing in this important area of patient care. 10 Building this evidence base is an extension of the Phase 3 and 4 studies that have been carried out by the Australian Palliative Care Clinical Studies Collaborative (PaCCSC).
11
Prospective data collection at agreed time points, using standardized measures of clinical harms and benefits, for medications that are frequently prescribed for symptom control in hospice/palliative care patients can provide important information. This is information specific to the clinical context of hospice/palliative care and cannot be provided by studying other patient populations. This method of rapid reporting allows immediate and short-term net clinical effects (benefits and harms) to be systematically studied during routine care.
A new pragmatic tool for pharmacovigilance was created 12 using secure Web-based technology, deidentified and unreidentifiable data, and a small number of set fields focusing on a single medication for a single indication (even if there are multiple indications for that medication in hospice/palliative care). By aggregating data from a large number of centers each of whom have provided data from a small number of consecutive participants who were commenced on haloperidol for delirium as part of routine clinical care, the evidence base of the real-world net effectiveness of this medication can be established. This process minimizes the work involved for individual clinicians, and represents a wide range of clinical settings and service delivery models.
Methods
The aim of this study was to describe the net clinical effect (i.e., the overall risk and benefit) of haloperidol when prescribed for delirium in a consecutive, prospective cohort of hospice/palliative care patients. All participating sites received ethical waivers (as the work falls under quality assurance, quality improvement, performance monitoring, clinical audit study type) or approval for low risk research depending on each site's Human Research Ethic Committee's assessment of this work. This meant that patients and/or family members did not need to be approached or consent provided for the study to proceed.
The study methods have been described in detail previously. 10 An expert committee defined prespecified clinical benefit and harm fields based on the available literature relating to the use of haloperidol for delirium ( Table 1 ). The National Cancer Institute's Common Toxicity Criteria for Adverse Events (NCI CTCAE) Likert scales for grading effects were used. 13 Nonidentifying demographic and clinical data were entered pro forma using a 128-bit encrypted Web portal (www.caresearch.com.au). Participants were consecutive patients at participating clinical sites started on haloperidol as part of routine clinical care for delirium.
Data were recorded at three set time points: baseline (the index symptom and symptoms that could reflect harm): 48 hours (index symptom (delirium) response), and 10 days (harms) after commencing haloperidol. The NCI criteria for delirium ask the clinician to rate overall severity of the symptoms but also impact on activities of daily living and other impacts (such as threats of harm to self or others; Table  2 ). This approach was chosen as the intention was to quantify the degree of impact from a symptom perspective and to align the assessment approaches of benefits and harms.
Overall benefit was defined as a 1-point reduction in the NCI CTCAE (for example severe to moderate, moderate to mild, mild to none) ( Table 2 ). Harms were attributed to haloperidol if the criteria for NCI CTCAE were greater than a baseline measurement at or before day 10 for that individual participant. For harms rated as 3 or greater on the NCI CTCAE criteria, data were collected on the Naranjo Score. This is a questionnaire designed to determine the attribution of an adverse drug reaction being due to the drug itself rather than other factors. In the hospice/palliative care setting only question 2, which explores the timing of the adverse events in relation to the medication being commenced, is reported. 14 Functional status was recorded using the Australian modified Karnofsky Performance Scale and comorbidities assessed using the Charlson Comorbidity Index. 15, 16 Statistical methods Univariable logistic regression model for each outcome on key clinical and demographic parameters was undertaken, clustering over site to account for correlated readings. Additionally, logistic regression was performed for each outcome on each pair of key parameters and their product term to identify possible subgroups that were associated with outcomes. We used multiple imputation to account for missing data, with 20 resamples drawn. Results are reported as odds ratios (OR) with 95% confidence intervals (CI). No adjustment was made for multiple comparisons as the results are considered to be hypothesis generating. A p value less than 0.05 (two-tailed) is considered statistically significant. Data were imported into Excel (Microsoft, Seattle, WA). All analyses were performed in STATA SE version 12.1 (StataCorp, College Station, TX).
Results
The clinical and demographic data of the study subjects are shown in Table 1 At 48 hours, 10 people had died and overall benefit was reported in 42 of 106 participants (35.2%; CI 26.6%-44.0%) of participants with recorded scores. (Table 3 , Figs. 1 and 2) . At the end of the study, a total of 52 people had died and 55 of 67 were still on regular haloperidol.
A total of 14 of 57 participants (24.6%; CI 13.0%-36.1%; Table 3 ) experienced 29 harms up to and including day 10 ( Table 4 ). The most frequently encountered harms were 
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somnolence (11; 9%) and urinary retention (6; 5%). Seven participants had their medication ceased for harms of whom two had somnolence and two had rigidity. In the logistic regression analyses, the Karnofsky score moderated the relationship between Charlson Comorbidity Index (CCI) and benefit from haloperidol. The higher the Karnofsky score the stronger the association between worsening comorbidity (higher CCI) and poorer response. For those with a median Karnofsky score of 30, subjects were approximately 12% less likely to benefit with each one point increase in CCI (OR = 0.88; CI 0.77 1.00; p = 0.043). For someone with a Karnofsky score of 60, subjects were approximately 39% less likely to benefit with each point increase in CCI (OR = 0.63; CI 0.43 0.99; p = 0.02). All other univariable and interaction analyses did not contain terms that were significant.
Discussion
Approximately 1 in 3 participants experienced benefit at 48 hours. Approximately 1 in 15 participants stopped haloperidol due to harms, 4 of which were graded 4. By using a multicenter, multinational, rapid, prospective design to reflect actual clinical practice, this study helps to understand the actual performance of medications in hospice/palliative care. The participants were mostly elderly (mean age, 73 years) and of poor physical functional status (mean AKPS 32). They had multiple comorbidities (CCI mean 5.7) prior to commencing treatment for delirium. Despite this clinical setting, haloperidol was relatively well tolerated in the immediate and short term. Of those with a documented harm, few were treated by a reduction in the dose or cessation of the medication.
There is little high-quality evidence available to guide the management of delirium in hospice/palliative care patients, particularly as people with this condition approach the end of their lives. 16 Systematic reviews have identified only a small number of studies, with a paucity of literature relating to the setting of people recognized to be approaching the end of life. However the findings of this study are consistent with systematic reviews. [18] [19] [20] Haloperidol is still recommended as the first-line agent in delirium management. 16 Of note, the doses reported by Campbell et al. 18 were much greater than those received by participants in this study (mean, 6.5 mg per 24 hours compared with 2.1 mg per 24 hours). (1) 3 (3) Yes n = 9 (22.5% CI 9.0%, 36.0%) 
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An important change to the first of these pharmacovigilance studies 12 was that harm was measured at baseline in addition to T 1 and T 2 and only worsening over baseline is reported. There were high baseline rates of somnolence 49 (41%), akathisia 13(11%), gait change 11(9%), and rigidity 7(6%) that may otherwise have been attributed to haloperidol.
Limitations
This study addresses only immediate and short-term harms. Harms of prolonged haloperidol administration such as some of the extrapyramidal effects will not be detected. Consistency of interpretation and measurement is a challenge for multicenter studies. This study also relies on clinicians recognizing delirium and utilizing a rating scale that only quantifies symptoms and some clinical impacts; rather than a detailed delirium scale with established psychometric properties. NCI CTCAE is conceived as a high-level screening tool for a wide range of symptoms and data are not available on its correlation with diagnostic tools for delirium. A project officer provided continuing e-mail updates and an information stream about the study to provide a central point of liaison for participating sites (Australia, New Zealand, Canada, and the United Kingdom).
Generalizability
Clinical sites were drawn from consultative services, ambulatory clinics and specialist inpatient hospice/palliative care units, reflecting the scope of current specialist palliative
FIG. 1.
Participant flow for the use of haloperidol in palliative care for delirium (n = 119; 14 sites; 4 countries). *Benefit is defined as ‡ 1-point reduction on the National Cancer Institutes' Common Toxicity Criteria for Adverse Events (NCI CTC AE) for delirium. **Harms are defined as ‡ 1-point increase over baseline for relevant NCE CTC AE score. Table 3 for explanation). This study demonstrates that when haloperidol is used for delirium, where the mean dose was 2.1 mg per 24 hours, it is relatively well tolerated, with relatively few immediate and short term side-effects. An adequately powered, multi-site, parallel arm Phase 3 double-blinded, randomized, placebocontrolled trial evaluating the additional net benefit of haloperidol in treating delirium in hospice/palliative care patients is nearing completion of accrual.
